PT - JOURNAL ARTICLE AU - Somerville, Emma N. AU - Krohn, Lynne AU - Yu, Eric AU - Rudakou, Uladzislau AU - Senkevich, Konstantin AU - Ruskey, Jennifer A. AU - Asayesh, Farnaz AU - Ahmad, Jamil AU - Spiegelman, Dan AU - Dauvilliers, Yves AU - Arnulf, Isabelle AU - Hu, Michele T.M. AU - Montplaisir, Jacques Y. AU - Gagnon, Jean-François AU - Desautels, Alex AU - Ibrahim, Abubaker AU - Stefani, Ambra AU - Hogl, Birgit AU - Gigli, Gian Luigi AU - Valente, Mariarosaria AU - Janes, Francesco AU - Bernardini, Andrea AU - Dusek, Petr AU - Sonka, Karel AU - Kemlink, David AU - Plazzi, Giuseppe AU - Antelmi, Elena AU - Biscarini, Francesco AU - Mollenhauer, Brit AU - Trenkwalder, Claudia AU - Sixel-Doring, Friederike AU - Figorilli, Michela AU - Puligheddu, Monica AU - De Cock, Valerie Cochen AU - Ferini-Strambi, Luigi AU - Heibreder, Anna AU - Monaca, Christelle Charley AU - Abril, Beatriz AU - Dijkstra, Femke AU - Viaene, Mineke AU - Boeve, Bradley F. AU - Postuma, Ronald B. AU - Rouleau, Guy A. AU - Gan-Or, Ziv TI - <em>NPC1</em> variants are not associated with Parkinson’s Disease, REM-sleep behaviour disorder or Dementia with Lewy bodies in European cohorts AID - 10.1101/2022.11.08.22281508 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.08.22281508 4099 - http://medrxiv.org/content/early/2022/11/08/2022.11.08.22281508.short 4100 - http://medrxiv.org/content/early/2022/11/08/2022.11.08.22281508.full AB - NPC1 encodes a lysosomal protein involved in cholesterol transport. Biallelic mutations in this gene may lead to Nieman-Pick disease type C, a lysosomal storage disorder. The role of NPC1 in alpha synucleinopathies is still unclear, as different genetic, clinical, and pathological studies have reported contradictory results. This study aimed to evaluate the association of NPC1 variants with the synucleinopathies Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and rapid eye movement (REM)-sleep behavior disorder (RBD). We analyzed common and rare variants from three cohorts of European descent: 1,084 RBD cases and 2,945 controls, 2,852 PD cases and 1,686 controls, and 2,610 DLB cases and 1,920 controls. Logistic regression models were used to assess common variants while optimal sequence Kernel association tests (SKAT-O) were used to assess rare variants, both adjusted for sex, age, and principal components. No variants were associated with any of the synucleinopathies, supporting that common and rare NPC1 variants do not play an important role in alpha synucleinopathies.Competing Interest StatementZiv Gan-Or has received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, UCB, Guidepoint, Lighthouse and Deerfield.Clinical Protocols https://github.com/gan-orlab/MIPVar Funding StatementThe work performed in this study was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canadian Institutes of Health Research (CIHR), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of McGill University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesREM-sleep behaviour disorder data produced in the present study is available upon request to the authors. Summary Statistics are available in the supplementary tables. Parkinson's disease data used in the present study is available online at https://amp-pd.org/. Dementia with Lewy bodies data used in the present study is available online at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001963.v1.p1. All results produced in the present study are contained in the manuscript. https://amp-pd.org/